| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.0014 | 1 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.00071 | 1 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.00059 | 1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.00061 | 1 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.0007 | 1 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.00056 | 1 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | -0.0017 | 1 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.00042 | 1 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.00062 | 1 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.00035 | 1 |